Fibroblast Growth Factor 23 and Mortality in Patients With Type 2 Diabetes and Normal or Mildly Impaired Kidney FunctionYeung, S. M. H., Binnenmars, S. H., Gant, C. M., Navis, G., Gansevoort, R. T., Bakker, S. J. L., de Borst, M. & Laverman, G. D., Nov-2019, In : Diabetes Care. 42, 11, p. 2151-2153 3 p.
Research output: Contribution to journal › Article › Academic › peer-review
OBJECTIVE To study whether fibroblast growth factor 23 (FGF23) is associated with adverse outcomes in patients with type 2 diabetes and normal or mildly impaired kidney function. RESEARCH DESIGN AND METHODS We analyzed C-terminal FGF23 levels in 310 patients with type 2 diabetes and estimated glomerular filtration rate >= 60 mL/min/1.73 m(2). Associations of FGF23 with all-cause mortality and major adverse cardiovascular events (MACE) were studied by Cox regression. RESULTS During a follow-up of 5.8 years (3.3-6.5), 47 patients developed MACE and 28 patients died. FGF23 was associated with an increased risk of all-cause mortality (age- and sex-adjusted hazard ratio 2.78 [95% CI 1.76-4.40]) and MACE (1.67 [1.12-2.49]). Results were similar after additional adjustment for other potential confounders and were consistent upon replication in an independent cohort. CONCLUSIONS In patients with type 2 diabetes and normal or mildly impaired kidney function, FGF23 is associated with an increased risk of cardiovascular events and mortality.
|Number of pages||3|
|Early online date||5-Sep-2019|
|Publication status||Published - Nov-2019|
- DISEASE, BONE